His primary scientific interests are in Prostate cancer, Internal medicine, Oncology, Surgery and Cancer. His research integrates issues of Prostate, Randomized controlled trial, Docetaxel and Hazard ratio in his study of Prostate cancer. Michael A. Carducci has included themes like Gastroenterology and Endocrinology in his Internal medicine study.
His Oncology research is multidisciplinary, relying on both Cabazitaxel, Clinical trial, Circulating tumor cell, Enzalutamide and Gynecology. Michael A. Carducci interconnects Placebo, Combination therapy, Peripheral edema and Urology in the investigation of issues within Surgery. His studies in Cancer integrate themes in fields like Adverse effect, Pharmacokinetics and Quality of life.
His scientific interests lie mostly in Internal medicine, Prostate cancer, Oncology, Cancer and Cancer research. His Internal medicine study combines topics in areas such as Endocrinology and Surgery. He has researched Prostate cancer in several fields, including Prostate, Docetaxel and Urology.
His Oncology research includes elements of Clinical endpoint, Enzalutamide, Proportional hazards model and Phases of clinical research. His studies deal with areas such as Pharmacokinetics and Pharmacology as well as Cancer. His Cancer research research incorporates elements of Histone deacetylase, Immunology and Pathology.
His primary areas of investigation include Internal medicine, Prostate cancer, Oncology, Cancer and Clinical trial. Hazard ratio, Disease, Nivolumab, Phases of clinical research and Enzalutamide are among the areas of Internal medicine where Michael A. Carducci concentrates his study. His Prostate cancer research integrates issues from Androgen, Randomized controlled trial, Docetaxel and Cancer research.
His biological study spans a wide range of topics, including Brief Pain Inventory and Urology. His work in the fields of Oncology, such as Renal cell carcinoma, overlaps with other areas such as SABR volatility model. Michael A. Carducci interconnects Health equity, Health literacy, Psychological intervention and Family medicine in the investigation of issues within Clinical trial.
Michael A. Carducci mainly investigates Internal medicine, Oncology, Prostate cancer, Nivolumab and Renal cell carcinoma. His study in Adverse effect, Clinical trial, Disease, Pazopanib and Prostate are all subfields of Internal medicine. His Oncology study combines topics in areas such as Cancer, Tolerability, Radiation therapy and Systemic therapy.
His Prostate cancer research is multidisciplinary, incorporating elements of Androgen, Randomized controlled trial, Docetaxel and Hazard ratio. His Nivolumab research also works with subjects such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Gary Hudes;Michael Carducci;Piotr Tomczak;Janice Dutcher.
The New England Journal of Medicine (2007)
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S. Antonarakis;Changxue Lu;Hao Wang;Brandon Luber.
The New England Journal of Medicine (2014)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney;Yu Hui Chen;Michael Carducci;Glenn Liu.
The New England Journal of Medicine (2015)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi;Michael Carducci;Matthew Smith;Ronaldo Damião.
The Lancet (2011)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris.
Journal of Clinical Oncology (2008)
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson.
Journal of Clinical Oncology (1999)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R Griffiths;Matthew W Johnson;Michael A Carducci;Annie Umbricht.
Journal of Psychopharmacology (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano.
Journal of Clinical Oncology (2016)
Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy
Milena Braga-Basaria;Adrian S. Dobs;Denis C. Muller;Michael A. Carducci.
Journal of Clinical Oncology (2006)
Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
Jonathan W Simons;Bahar Mikhak;Ju-Fay Chang;Angelo M DeMarzo.
Cancer Research (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: